RNA Analytical/Quality Videos

  1. The Evolutions Of mRNA Analytical Development (So Far) 8/22/2024

    Linear mRNA analytical development has been rapidly advancing in the past few years and this panel discussion explores some of the biggest changes we’ve seen in the linear mRNA analytical paradigm.

  2. Navigating the Continuum of LNP Analytical Knowledge 6/9/2026

    In this clip, Advancing RNA Live speakers Elaine Peters, Philippe Talaga, and Ilya Shestopalov advocate for an orthogonal approach as we strive to better understand our LNP QAs — with particular attention paid to particle size.   

  3. What Learnings Can mRNA Take From The Oligonucleotide Regulatory Paradigm? 5/10/2024

    ReciBioPharm’s Melanie Cerullo shares where mRNA needs to “catch up” to its oligonucleotide “cousin” molecules and where regulatory differences may be emerging between modalities.

  4. The Strategic Shift(s) In gRNA CMC 4/29/2026

    In this opening Advancing RNA Live clip, panelists Max De Long, April Sena, and Venkat Krishnamurthy share the biggest scientific and manufacturing breakthrough made in the world of gRNA production over the past year. 

  5. Quality Concepts In GMP IVT mRNA Development, Manufacturing, And Analytics 2/13/2025

    Stay ahead in mRNA therapeutic development by mastering the essential quality systems, process controls, and analytical methods required for robust GMP production and efficient manufacturing.

  6. Fermentation, Analytics, & Quality: Plasmid Production Advancements & Challenges for mRNA Development 4/11/2025

    Advancing RNA Live panelists Tyler Goodwin and April Sena start off our latest discussion on technology innovations in mRNA production by surveying the current manufacturing process for plasmid production, highlighting where they’ve seen advancements and what biotechs need to consider to obtain plasmids of the appropriate quality for mRNA production.

  7. Decoding Regulatory Expectations: The Art Of A Successful IND Submission 6/24/2025

    Companies often underestimate the information required for IND submissions, particularly in a sector that’s as diverse as the mRNA sector. Here, former FDA reviewer Tiffany Lucas shares some of the missteps companies can make when first approaching the FDA with their IND. CureVac’s Ulrike Jägle furthers the discussion, offering a critical best practice she and her colleagues rely upon as well to streamline their regulatory interactions.

  8. Therapeutic Market Opportunities For mRNA 10/16/2023

    In this segment from the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development, hundreds of audience members tell us what forms of vaccine and therapeutics they’re developing.

  9. Advancing Peptide Characterization Of Critical Quality Attributes With MMS 11/12/2025

    Axxium uncovered hidden peptide aggregation using MMS technology, revealing process-related potency issues missed by conventional methods. Learn how advanced structural analysis can strengthen quality control and biologics development.

  10. Improving IVT Processes: Addressing Analytical Limitations & PAT Shortcomings 4/11/2025

    Advancing RNA Live panelists identify what is “as good as we can get right now” in terms of understanding our IVT reactions while sharing their ideas on how we can arrive at a future that includes real-time monitoring of our drug substance production processes.